Biotech investors in New York
This slice of our investor database holds 56 Biotech New York investors. All of them are in New York. The sectors they back most often here are Biotech (56), Health tech (46) and AI (38). The median firm in this slice has made 54 investments; across the slice the total is 9,007. The median number of exits is 5. By stage: Pre-seed (35), Seed (51), Series A (49), Series B (31) and Growth (24). The largest portfolios in this slice belong to General Catalyst, First Round and Greycroft. Every row below is shown in full except the contact details, which are the paid part of the dataset. The numbers on this page are recomputed from the database, so they change when the data does.
- 56 firms in this slice.
- Most concentrated in New York (56).
- Median investments per firm: 54.
- Leading sector: Biotech (56).
- 56 rows carry a contact address; those are the paid part.
| By stage | Investors |
|---|---|
| Pre-seed | 35 |
| Seed | 51 |
| Series A | 49 |
| Series B | 31 |
| Growth | 24 |
| By sector | Investors |
|---|---|
| biotech | 56 |
| healthtech | 46 |
| ai | 38 |
| saas | 38 |
| foodtech | 33 |
| fintech | 31 |
| data-analytics | 29 |
| enterprise | 27 |
| manufacturing | 26 |
| climate | 25 |
| By city | Investors |
|---|---|
| New York | 56 |
| By type | Investors |
|---|---|
| Venture funds | 50 |
| Accelerators | 2 |
| Family offices | 2 |
| Corporate VC | 1 |
| Angel networks | 1 |
Number of investments made, by firm.
| Portfolio size | Investors |
|---|---|
| 0–10 | 7 |
| 10–25 | 6 |
| 25–50 | 12 |
| 50–100 | 9 |
| 100+ | 22 |
Preview — 15 of 56
| Investor | Type | Location | Stages | Investments | Contact |
|---|---|---|---|---|---|
| General Catalyst | Venture funds | New York, US | Series B, Seed, Growth, Pre-seed, Series A | — | |
| First Round | Venture funds | New York, US | Seed | — | |
| Greycroft | Venture funds | New York, US | Series B, Seed, Growth, Pre-seed, Series A | — | |
| OrbiMed | Venture funds | New York, US | Series B, Seed, Growth, Series A | — | |
| BoxGroup | Venture funds | New York, US | Series B, Seed, Growth, Pre-seed, Series A | — | |
| Gaingels | Angel networks | New York, US | Series B, Seed, Growth, Pre-seed, Series A | — | |
| Warburg Pincus | Venture funds | New York, US | Series B, Growth | — | |
| General Atlantic | Venture funds | New York, US | Growth | — | |
| Lux Capital | Venture funds | New York, US | Series B, Seed, Growth, Pre-seed, Series A | — | |
| StartUp Health | Venture funds | New York, US | Seed, Pre-seed, Series A | — | |
| FirstMark Capital | Venture funds | New York, US | Series B, Seed, Growth, Series A | — | |
| Compound | Venture funds | New York, US | Seed | — | |
| Bill & Melinda Gates Foundation | Family offices | New York, US | Series B, Seed, Growth, Series A | — | |
| Two Sigma Ventures | Venture funds | New York, US | Seed, Pre-seed, Series A | — | |
| The Fund | Venture funds | New York, US | Seed, Pre-seed | — |
Questions
What is free here?
Name, type, stages, sectors, city and country, website, investment and exit counts — as aggregates across all 56 rows and row by row for the first fifteen. Contact addresses are not part of the free view and are physically absent from this page.
What does buying add?
The full export of all 56 rows in XLSX and CSV, including contact email (56 rows have one). Access follows the list, not a file: the export is rebuilt and you always download the current version.
Where does the data come from?
Source and method are described on the investor data sources page. We do not claim verification that did not happen — each row carries a confidence level. An investor who asks to be excluded is removed from both the preview and the export.
Where this data comes from · updated 9/5/2026